Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo- -lactamase

Abstract

Stay in an ICU, prior use of carbapenems and prior exposure to >3 different classes of antibiotics were independent predictors for VPKP BSIs. These findings provide guidance for antibiotic policies and infection control strategies to contain the spread of VPKP.

Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit

“…Other studies reported that the administration of almost all broad-spectrum antibiotics and not just carbapenems could facilitate the development of infections due to CRKp or CRE in general. 24,25 The mortality rate in this study was high for patients with both CRKp and CSKp infections. Notably, 21% of them died within 2 days from the onset of the infection.…”

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

“…Several investigators have evaluated the factors associated with increased risk for acquisition of CPE in the hospital setting (69,91,98,106,117,132,205,233,261). Investigators from Israel have shown that poor functional status of the host, prior antibiotic therapy, and stay in the ICU are independent risk factors for colonization or infection with carbapenem-resistant K. pneumoniae (233).…”

“…Case-control studies have shown that almost every class of antibiotics can select for CPE (69,91,98,117,120,132,203,261). What appears to be more important, however, is the cumulative number of prior antibiotic exposures rather than the use of a specific class of antibiotics (69,205). Since members of the Enterobacteriaceae constitute part of the human enteric flora, once CPE colonize the intestinal tract, carriage may persist for a long time (232).…”

Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology

“…[82][83][84][85][86][87][88][89][90] Are carbapenems the drugs of choice for the treatment of invasive infections caused by ESBL-producing Enterobacteriaceae?…”